BPC-157 official-source update · version 2

This page preserves this version’s findings and source pins. Open the current profile →

Official-source update

Reviewed 2026-09-19 · Preserved version 2

FDA’s review focused on ulcerative colitis

FDA evaluated BPC-157 free base and acetate separately for ulcerative colitis. The briefing recommended against their inclusion on the 503A bulks list. It explicitly precedes a final agency determination; this summary does not report a final ruling. FDA PDF pp. 1, 5, 8, 9 ↗FDA PDF pp. 43, 44, 45, 46, 47 ↗

More findings and the sources behind them

Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.

The human trial evidence was limited

FDA identified a 53-participant, two-week randomized study reported only in a meeting abstract. Missing endpoint, eligibility, statistical and follow-up details prevented it from supporting efficacy and safety conclusions for ulcerative colitis. FDA PDF pp. 25, 27, 28, 29 ↗

Formulation and duration limit extrapolation

The reviewed trial used a rectal enema, not the nominated suppository. FDA found no ulcerative-colitis studies using the proposed oral, subcutaneous, nasal or transdermal routes. These findings cannot establish effectiveness for tendon or sports injuries. FDA PDF pp. 1, 5, 8, 9 ↗FDA PDF pp. 25, 27, 28, 29 ↗

Safety remains inadequately characterized

FDA described insufficient clinical safety information, limited long-term data and concerns involving peptide impurities, aggregation and immune responses. Its adverse-event reports could not establish causality. FDA PDF pp. 43, 44, 45, 46, 47 ↗

Rectal-enema findings do not validate other formulations

The briefing distinguishes the studied rectal enema from the nominated suppository and other routes. FDA found no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal administration in its reviewed sources. FDA PDF pp. 27, 40 ↗

Assay experiments are not human treatment studies

FDA identified laboratory plasma-metabolism reports used for anti-doping detection in which BPC-157 was not administered to people. Such work must not be counted as a clinical exposure study. FDA PDF pp. 40 ↗

Reported adverse events cannot establish causation or incidence

FDA discussed injection-related reports but noted incomplete information and concomitant substances. Those reports neither prove that BPC-157 caused each event nor establish a reliable adverse-event rate. FDA PDF pp. 41, 44 ↗

What remains to be checked

Check subsequent advisory records and any final FDA action separately from the staff briefing.
Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.

Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

FDA BPC-157 briefing for the July 2026 advisory meeting ↗
Source dated 2026-05-11; retrieved 2026-09-16.
- Briefing boundary and evaluation scope · PDF pp. 1, 5, 8, 9 of 68
- Effectiveness evidence for ulcerative colitis · PDF pp. 25, 27, 28, 29 of 68
- Safety conclusions and recommendation · PDF pp. 43, 44, 45, 46, 47 of 68
SHA-256: 339602f311095bb9baa023f102186a659ea6871c3f5a4dc7f811036182764d14
FDA bpc-157 briefing for the July 2026 advisory meeting ↗
Source dated 2026-07-23; retrieved 2026-09-19.
- The ulcerative-colitis evidence was a short meeting abstract · PDF pp. 27, 28 of 68
- Rectal-enema findings do not validate other formulations · PDF pp. 27, 40 of 68
- Assay experiments are not human treatment studies · PDF pp. 40 of 68
- Reported adverse events cannot establish causation or incidence · PDF pp. 41, 44 of 68
SHA-256: 339602f311095bb9baa023f102186a659ea6871c3f5a4dc7f811036182764d14

Open versioned findings and source records →